Sight Sciences announced FDA 510(k) clearance for its OMNI Ultra Surgical System, a minimally invasive glaucoma surgery (MIGS) device designed for single pass canaloplasty and trabeculotomy to reduce intraocular pressure in adults with primary open-angle glaucoma. The OMNI Ultra offers implant-free intervention addressing all three areas of aqueous outflow resistance through a single microincision, featuring TruSync Plus technology for enhanced control and precision. This clearance marks a significant advancement in glaucoma treatment, with the commercial launch planned for Q4 2026. The device supports both standalone and combined cataract surgeries, aiming to improve surgical outcomes and patient care.
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Beetaloo Energy is close to starting pilot gas sales from its Carpentaria Pilot Project, with the gas plant in final construction stages and major equipment onsite. The Carpentaria-5H well showed strong performance, producing 6.7 terajoules per day o...
